Literature DB >> 6791202

Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.

D Pickar, R M Cohen, D C Jimerson, D L Murphy.   

Abstract

The enhanced sensitivity to the pressor effects of tyramine, an indirect-aging sympathomimetic found abundantly in the diet, is a well-known potentially dangerous side effect occurring during treatment with commonly used non-selective monoamine oxidase (MAO) inhibitors. The effects of treatment with the selective MAO-A inhibitor clorgyline and the partially selective MAO-B inhibitors pargyline and deprenyl on tyramine's pressor effects were studied in depressed patients using an IV steady-state tyramine infusion technique. After 4 weeks of treatment, clorgyline produced a significantly greater increase in tyramine sensitivity in comparison to a medication-free baseline (29-fold) than did pargyline (12-fold) or deprenyl (1.7-fold). The pressor effects of tyramine were significantly prolonged after cessation of infusion during both clorgyline and pargyline, but not deprenyl treatment. These data from IV tyramine administrations suggest that intestinal MAO inhibition is not the major determinant of the enhanced tyramine pressor sensitivity produced by clorgyline and pargyline.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6791202     DOI: 10.1007/BF00431747

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

Review 1.  Multiple forms of monoamine oxidase: fact and artefact.

Authors:  M D Houslay; K F Tipton
Journal:  Life Sci       Date:  1976-08-15       Impact factor: 5.037

2.  HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS.

Authors:  B BLACKWELL
Journal:  Lancet       Date:  1963-10-26       Impact factor: 79.321

3.  Metabolism of norepinephrine-H3 released by tyramine and reserpine.

Authors:  I J KOPIN; E K GORDON
Journal:  J Pharmacol Exp Ther       Date:  1962-12       Impact factor: 4.030

4.  Treatment of hospitalized depressed and schizophrenic patients with monoamine oxidase inhibitors: including reflections on pargyline.

Authors:  J C SAUNDERS
Journal:  Ann N Y Acad Sci       Date:  1963-07-08       Impact factor: 5.691

Review 5.  Substrate-selective monoamine oxidases--inhibitor, tissue, species and functional differences.

Authors:  D L Murphy
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

Review 6.  Interactions of monoamine oxidase inhibitors, amines, and foodstuffs.

Authors:  E Marley; B Blackwell
Journal:  Adv Pharmacol Chemother       Date:  1970

7.  Biochemical aspects of release of norepinephrine and other amines from sympathetic nerve endings.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

8.  Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.

Authors:  S Lipper; D L Murphy; S Slater; M S Buchsbaum
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

9.  Tyramine infusions in bipolar illness: behavioral effects and longitudinal changes in pressor sensitivity.

Authors:  D Pickar; R M Cohen; D L Murphy; D Fried
Journal:  Am J Psychiatry       Date:  1979-11       Impact factor: 18.112

10.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

View more
  10 in total

1.  Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.

Authors:  A Prasad; V Glover; B L Goodwin; M Sandler; M Signy; S E Smith
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences.

Authors:  I W Reimann; L Firkusny; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  COMT inhibition with nitecapone does not affect the tyramine pressor response.

Authors:  S Sundberg; A Gordin
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

4.  Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

Authors:  V Glover; C J Pycock; M Sandler
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

Review 5.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

6.  Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction.

Authors:  D Pickar; R M Cohen; D C Jimerson; C R Lake; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Tyramine pressor sensitivity changes during deprenyl treatment.

Authors:  T Sunderland; E A Mueller; R M Cohen; D C Jimerson; D Pickar; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

Authors:  B Hazelhoff; J B De Vries; D Dijkstra; W de Jong; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

9.  Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.

Authors:  P Bitsios; R W Langley; S Tavernor; K Pyykkö; M Scheinin; E Szabadi; C M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

10.  Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.

Authors:  J W Lenders; G Eisenhofer; N G Abeling; W Berger; D L Murphy; C H Konings; L M Wagemakers; I J Kopin; F Karoum; A H van Gennip; H G Brunner
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.